Fast Track for an AI Drug: Insilico's ISM6331 Wins FDA Priority Review Path in Mesothelioma

Regulatory milestones for AI-discovered molecules remain rare enough that each one carries outsized signal value. On July 29, 2026, Insilico Medicine announced that ISM6331, a pan-TEAD inhibitor designed using the company's generative AI platform, received FDA Fast Track Designation for adult patients with unresectable malignant pleural mesothelioma whose disease has progressed after prior anti-PD-1 therapy (with or without anti-CTLA-4) and platinum-based chemotherapy.

This is the first Fast Track Designation granted to a program in Insilico's AI-driven pipeline — a regulatory acknowledgment that the compound may address an unmet need in a disease with limited treatment options.

The science behind ISM6331

TEAD (TEA domain transcription factors) proteins are key effectors of the Hippo signaling pathway, which regulates cell proliferation and organ size. Pan-TEAD inhibition targets a mechanism implicated in multiple tumor types, including mesothelioma.

Insilico reports that ISM6331 demonstrated in preclinical studies:

• Broad anti-tumor efficacy across models
• Potent activity at low doses
• A favorable safety profile with favorable ADMET characteristics

The compound was previously featured at the AACR 2024 Annual Meeting. Initial Phase I first-in-human clinical data has been accepted for a brief oral presentation at the upcoming ESMO 2026 Congress.

Regulatory timeline

Insilico's regulatory path for ISM6331 includes:

• June 2024: FDA Orphan Drug Designation for mesothelioma
• January 2025: First patient dosed in global multicenter Phase I trial
• July 2026: FDA Fast Track Designation

Fast Track is designed to facilitate development and expedite review of drugs treating serious conditions with unmet medical need. It enables more frequent FDA interactions and potential rolling review of application components.

Context in Insilico's pipeline

ISM6331 is distinct from Insilico's lead program Rentosertib (ISM001-055), a first-in-class AI-discovered TNIK inhibitor now in Phase III development for idiopathic pulmonary fibrosis (IPF). Rentosertib received Orphan Drug Designation in February 2023.

Insilico, listed on the Hong Kong Stock Exchange (3696), has nominated 31 preclinical candidates, received over 10 IND clearances, and reports compressing time-to-PCC nomination to roughly 12–18 months versus the 2.5–4-plus years typical of traditional discovery.

The Fast Track for ISM6331 validates a narrower claim: that AI-designed molecules can earn the same regulatory accelerators as conventionally discovered compounds when clinical rationale and early data support it.

What Fast Track does — and does not — mean

Fast Track Designation is not approval. It does not guarantee clinical success or shorten Phase I safety evaluation. Mesothelioma remains a difficult indication with historically poor outcomes.

What it does signal: FDA reviewers see sufficient preliminary evidence and unmet need to prioritize development resources. For Insilico's investors and the broader AI-drug-discovery sector, that is a tangible bridge between algorithmic design and regulatory reality.

Industry watch

Insilico's milestone arrives amid a broader push to validate AI-native drug discovery beyond benchmark exercises. Relation Therapeutics unveiled its MORGAN cellular foundation model and a $110 million GSK collaboration on July 30. Insilico itself launched DDD Benchmarks as a Service on July 30 to standardize evaluation of frontier AI in drug discovery.

The sector is bifurcating: companies proving regulatory traction for individual molecules, and companies building the data infrastructure to train the next generation of discovery models. ISM6331's Fast Track belongs to the first column — and it is the most concrete regulatory win Insilico has posted for an AI-designed oncology asset to date.

### Sources

• Insilico Medicine / PRNewswire — Insilico Medicine Receives FDA Fast Track Designation for ISM6331 (July 29, 2026)
• FDA — Fast Track Designation Program (policy reference)
• Insilico Medicine — Corporate pipeline disclosures (HKEX: 3696) (July 2026)